Morbidity and mortality with dihydropyridines

Blood Pressure

Volumn 7, Issue SUPPL. 1, 1998, Pages 30-32

  Hansson, Lennart ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

calcium antagonists; cancer; cardiovascular morbidity; dihydropyridines

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; NIFEDIPINE;

ARTICLE; CARDIOVASCULAR DISEASE; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; ANTIHYPERTENSIVE THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; HEART INFARCTION; PRIORITY JOURNAL;

CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DIHYDROPYRIDINES; HUMANS; HYPERTENSION; MORBIDITY;

EID: 80052124802     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/080370598438582     Document Type: Conference Paper

References (17)

1. Hansson L, Dahlöf B, Gudbrandsson T, et al. Antihypertensive effect of felodipine or hydralazine when added to beta-blocker therapy. J Cardiovasc Pharmacol 1988; 12: 94-101.
2. Gong L, Zhang W, Zhu Y, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14: 1237-45. (Pubitemid 26343504)
3. Amery A, Birkenhäger WH, Bulpitt CJ, et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol, and organization. Aging 1991; 3: 287-302.
4. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-5.
5. Aursnes I, Litleskare I, Frøyland H, Abdelnoor M. Association between various drugs used for hypertension and risk of acute myocardial infarction. Blood Press 1995; 4: 157-63.
6. Leader SG, Mallick R, Briggs NC. Myocardial infarction in newly diagnosed hypertensive Medicaid patients free of coronary heart disease and treated with calcium channel blockers. Am J Med 1997; 102: 150-7. (Pubitemid 27125909)
7. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-31.
8. Pahor M, Curalnik JM, Salive ME, Corti M-C, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 9: 695-9. (Pubitemid 26266609)
9. Pahor M, Curalnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996; 348: 493-7. (Pubitemid 26279010)
10. Pahor M, Curalnik J, Furberg C, Carbonin P, Havlik R. Risks of gastrointestinal haemorrhages with calcium antagonists in hypertensive patients over 67 years old. Lancet 1996; 347: 1061-5. (Pubitemid 26118892)
11. Jick H, Jick S, Derby IE, Vasilakis C, Wald Myers M, Meier CR. Calcium-channel blockers and risk of cancer. Lancet 1997; 349: 525-8. (Pubitemid 27092790)
12. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organization and the International Society of Hypertension. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J Hypertens 1997; 15: 105-15.
13. Hansson L, Zanchetti A, for the HOT Study Group. The Hypertension Optimal Treatment (HOT) Study-Patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Press 1994; 3: 322-7. (Pubitemid 24325855)
14. Lindholm LH, Hansson L, Dahlöf B, et al. The Swedish Trial in Old Patients with Hypertension (STOP-Hypertension-2): a progress report. Blood Press 1996; 5: 300-4. (Pubitemid 26290694)
15. The NORDIL Study Group. The Nordic Diltiazem Study. An intervention study in hypertension comparing calcium antagonist based treatment with conventional therapy. Blood Press 1993; 2: 312-21.
16. Staessen JA, Fagard R, Thijs L, et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-64. (Pubitemid 27387202)
17. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-6.